Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Sphingosine kinases (SphKs) phosphorylate sphingosine to generate sphingosine-1-phosphate (S1P).
• S1P is a bioactive lipid mediator involved in diverse biological functions.
• Dysregulation of S1P signaling is linked to inflammatory diseases, Alzheimer's disease, and cancer.

Purpose of the Study:

• To review recent advancements in the research of SphK inhibitors.
• To provide a comprehensive overview for selecting specific pharmacological profiles of SphK inhibitors.

Main Methods:

• Literature review of recent research on SphK inhibitors.
• Analysis of distinct mammalian SphK isoforms (SphK1 and SphK2).

Main Results:

• Two mammalian SphK isoforms, SphK1 and SphK2, exist with distinct properties and functions.
• Inhibition of SphK1 and SphK2 holds therapeutic potential in various pathological conditions.
• Compensatory mechanisms between SphK isoforms necessitate the development of dual inhibitors.

Conclusions:

• SphK1 and SphK2 share commonalities but possess different biological functions.
• Targeting SphKs offers therapeutic potential, with ongoing research into selective and dual inhibitors.
• Understanding isoform-specific functions and compensatory mechanisms is crucial for effective SphK inhibitor development.